CSL's (ASX:CSL) Switzerland-based pharmaceutical unit, CSL Vifor, and US biopharmaceutical firm Travere Therapeutics said the European Commission has granted standard marketing authorization for Filspari, a treatment for primary IgA nephropathy (IgAN), a rare and progressive kidney disease, according to a Tuesday statement by the company.

The decision converts a previous conditional marketing authorization and extends to all European Union member states, as well as Iceland, Liechtenstein, and Norway, the company said.

Filspari was developed by Travere Therapeutics and exclusively licensed to CSL Vifor for commercialization in Europe, Australia, and New Zealand.

CSL's shares rose 1% in recent Wednesday trade.